RGNXbenzinga

REGENXBIO Presents Interim Data From Two Patients In Phase I/II Portion Of AFFINITY DUCHENNE Trial Of RGX-202 At 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 19, 2025 by benzinga

    REGENXBIO Presents Interim Data From Two Patients In Phase I/II Portion Of AFFINITY DUCHENNE Trial Of RGX-202 At 2025 Muscular Dystrophy Association Clinical & Scientific Conference | RGNX Stock News | Candlesense